Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistency of Response to Omalizumab in Severe Allergic Asthma
NCT00264849Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2005
- Primary completion
- Sep 2008
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 4, randomised, open-label trial of omalizumab in allergic asthma (2 arms), sponsored by Novartis. Primary endpoint: Persistency of Response and Non-response as Based on Investigator's Global Evaluation of Treatment Effectiveness at 32 weeks. Started Nov 2005; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00264849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264849.